The latest settlement involves a practice known as ‘off-label marketing’ in which drugmakers push medicines for uses beyond those approved by the regulator.

Connecticut and 43 other states have joined in a settlement with the British pharmaceutical firm GlaxoSmithKline (GSK) to resolve allegations of unlawful promotion of the asthma drug, Advair, and antidepressants Paxil and Wellbutrin.